Last week, Rowan University’s Board of Trustees committed $50 million over 10 years to significantly enhance medical and bioscience research at the Cooper Medical School of Rowan University (CMSRU) in the City of Camden. Cooper University Health Care’s Board voted today committing to a collaborative effort to build a first-rate medical research program focused on recruiting top research and clinical faculty to develop breakthrough medical cures and treatments.
“Medical research programs, as we envision at Cooper Medical School of Rowan University, have great potential to impact education, our health care system, and the economy,” said Ali A. Houshmand, president of Rowan University. “We believe this investment and the collaboration with Cooper University Health Care physicians will build upon CMSRU’s strong reputation and strengthen Camden’s ‘eds and meds’ corridor as an important destination for medical and bioscience research, and is in keeping with our recent designation as a Carnegie research institution.”
According to Houshmand, Rowan’s investment will add further momentum to the City of Camden’s revitalization efforts and create a new economic opportunities in the “eds and meds” corridor. The funding will be used, in part, to develop programs, attract top researchers, and provide seed money and start-up costs for researchers.
“As the leading academic health system in South Jersey, Cooper knows how significant medical and bioscience research programs are to developing the next generation of breakthrough treatments and cures,” said Cooper University Health Care Chairman George E. Norcross, III. “Cooper’s Board is in full support of Rowan’s investment and committed to creating a first-rate research program at CMSRU. Attracting top students and health care professionals benefits patients, it benefits our health care system and it provides additional economic opportunities in Camden.”Related Articles: